Recurrent epithelioid trophoblastic tumor with complete response after surgery, chemotherapy, and immunotherapy: A case report and literature review Authors: Lingting Meng, Bin Yang, Jiaqi Ma, Juan Zhang, Lei Lei, Ye Hong, Xiaojun Hu Published: 2026 ABSTRACT AbstractBackground:Epithelioid trophoblastic tumor (ETT) is the rarest form of gestational trophoblastic neoplasm, accounting for 1.39–2% of gestational trophoblastic diseases. Its clinical behavior and pathogenesis remain poorly understood, and no standardized treatment guidelines currently exist, with surgery considered the most important therapeutic option. Emerging modalities, including immune checkpoint inhibitors, are under investigation.Case presentation:We report a case of recurrent ETT achieving complete response after combined surgery, chemotherapy and immunotherapy. Notably, the primary tumor arose from the urachus, without uterine involvement; to the best of our knowledge, this presentation has not previously been reported.Conclusion:The present case highlights a novel primary site for ETT and suggests the potential efficacy of multimodal therapy, including immunotherapy, in managing recurrent disease.Keywords: Epithelioid trophoblastic tumor, Recurrent, Urachus, Immunotherapy Introduction Gestational trophoblastic neoplasms (GTNs) are a distinct histological subtype of gynecological malignancies and are among the first solid tumors in humans to achieve curative treatment. The incidence rates vary by region, ethnicity and type of pregnancy. Globally, the incidence of GTN ranges from 3 to 23 cases/100,000 deliveries, and is thus considered a rare tumor. GTN encompasses choriocarcinoma, placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). In clinical practice, invasive hydatidiform mole is also classified as a GTN. PSTT and ETT are collectively classified as intermediate trophoblastic tumors (ITTs) (Lu and Chen, 2014). Notably, ETT is the rarest form of GTN, and was previously regarded as a low-grade malignancy resembling PSTT, with treatment strategies largely following those used for PSTT. However, recent evidence has indicated that ETT exhibits markedly higher malignant potential than PSTT, and once metastasis or recurrence occurs, the clinical outcome is often fatal. ETT typically arises in women of reproductive age and may develop following any type of pregnancy, most commonly after term gestation (Zhang et al., 2014). Abnormal vaginal bleeding is the most frequent presenting symptom (Horowitz et al., 2017), although asymptomatic cases have been reported (Davis et al., 2015). The tumor most often originates in the lower uterine segment and cervix, but in rare instances, extrauterine metastatic lesions may be the sole manifestation, involving sites such as the vagina, fallopian tubes, broad ligament, lungs or liver. The present case is reported to raise awareness of this rare tumor, to improve diagnostic and therapeutic strategies, and to highlight the potential role of immune checkpoint inhibitors (ICIs) in selected patients. Case report First surgery and pathology A 47-year-old female patient was admitted to the Department of Urology at the Second Affiliated Hospital of Shaanxi University of Chinese Medicine on December 7, 2022, due to a urachal cyst detected during routine health examination via urinary system ultrasound. The urinary ultrasound revealed a urachal cyst measuring approximately 5 × 4.3 × 3.1 cm. The serum level of beta-human chorionic gonadotropin (β-hCG) was measured at 20 IU/L. However, the abnormal HCG value failed to be taken into consideration in the treatment plan. First surgery and pathology. The patient underwent surgical excision of the urachal cyst on December 9, 2022. Postoperative pathology revealed a urachal tumor highly suggestive of ETT. Further evaluation of the uterus was recommended to exclude uterine metastasis before considering an extrauterine primary origin. A pathology consultation at the First Affiliated Hospital of Xi'an Jiaotong University confirmed a malignant epithelioid tumor with necrosis involving the extraperitoneal pelvic tissue and right rectus abdominis muscle. Based on morphology and immunohistochemistry (IHC), the diagnosis of ETT was supported. No further examination of the uterus was conducted or therapy administered, and the patient did not undergo regular follow-up. Second surgery and pathology On February 19, 2024, an abdominal ultrasound revealed a 6.8 × 6.0 × 4.3 cm mass. The patient was admitted to Shaanxi Cancer Hospital with the diagnosis of ‘rectus abdominis mass for 1 month’. The patient reported no other specific discomfort. Physical examination revealed a 5-cm mass that was palpable in the right lower abdomen, with mild tenderness and poor mobility. Gynecological examination revealed a normal vulva and vagina, a smooth cervix with a diameter of 3.5 cm and no contact bleeding. The uterus was anteverted, of normal size and consistency, and mobile without tenderness. No adnexal masses were detected bilaterally. Rectovaginal examination showed no abnormalities. Laboratory and imaging studies revealed that the serum β-hCG level was 2.6 IU/l and the computed tomography (CT) scan of the brain and chest was unremarkable. An abdominopelvic magnetic resonance imaging (MRI) scan revealed a nodular lesion (2.1 × 1.5 × 2.1 cm) posterior to the right rectus abdominis at the prior surgical site, showing isointensity on T1WI and hyperintensity on T2WI, consistent with tumor recurrence (Fig. 1). Pathological review of prior surgical specimens supported the diagnosis of ETT. (A) Axial plane, (B) Sagittal plane. Pelvic MRI demonstrated a mass lesion located in the right extraperitoneal space, between the parietal peritoneum and the rectus abdominis muscle. The lesion exhibited heterogeneous signal intensity on T2-weighted images, with areas of high signal suggestive of necrosis. There was evident infiltration into the adjacent skeletalmuscle of the rectus abdominis. Second surgery and pathology. On February 20, 2024, the patient underwent resection of the abdominal wall mass, total hysterectomy and bilateral salpingectomy. During the operation, a 5-cm mass was found beneath the right rectus abdominis, adherent to the rectus muscle and peritoneum, with friable consistency. The uterus, adnexa and abdominal cavity showed no gross abnormalities. Pathological examination revealed that the abdominal wall tumor measured 6.5 × 5.0 × 1.1 cm (Fig. 2A). Histology was consistent with ETT infiltrating skeletal muscle (Fig. 2B). Additional findings included proliferative endometrium, chronic cervicitis and bilateral fallopian tubes without pathology. IHC results were as follows: Human placental lactogen (hPL) (−), inhibin-α (+) (Fig. 2C), placental alkaline phosphatase (PLAP) (+) (Fig. 2D), β-hCG-α (−), GATA-3 (+) (Fig. 2E), cytokeratin (CK)7 (+) (Fig. 2F), CK20 (−), Vim (−), P63 (+), CK5/6 (−), uroplakin (−), CD117 (−), spalt-like transcription factor 4 (−), Oct3/4 (−), D2–40 (−), CK8/18 (+) and programmed death-ligand 1 (PD-L1) [E1L3N, combined positive score (CPS): 80] (Fig. 2G). (A) General specimens, the specimen presented as a solid mass with poorly defined borders, a friable texture, and areas of grossly identifiable necrosis. (B) Pathological examination at low magnification showed tumor cells are arranged in diffuse sheets and exhibit relatively uniform epithelioid morphology. The cell borders are distinct with eosinophilic cytoplasm. The nuclei are round to oval, featuring fine chromatin and occasional small nucleoli. Characteristic fibrinoid necrotic foci are observed between the tumor cell nests (H&E; magnification, x10). (C)Ihinbin,(IHC, DAB staining; magnification, x10). (D)PLAP, (IHC, DAB staining; magnification, x10). (E)GATA3,(IHC, DAB staining; magnification, x10). (F)CK7, (IHC, DAB staining; magnification, 10). (G)PD-L1, (IHC, DAB staining; magnification, x10). Adjuvant treatment and outcome Postoperatively, the patient received combination chemotherapy and immunotherapy with the EMA-CO regimen and camrelizumab. The regimen included camrelizumab, 240 mg; actinomycin-D, 1 mg; etoposide, 300 mg; methotrexate, 450 mg; vincristine, 2 mg; and cyclophosphamide, 0.9 g; administered biweekly for four cycles. The treatment course was uneventful without severe chemotherapy- or immunotherapy-related adverse events. β-hCG levels remained within the normal range (0.148–2.6 IU/l) throughout treatment. Although maintenance therapy with camrelizumab was recommended, the patient refused. The patient is currently under regular surveillance, including gynecological examination, serum β-hCG, chest CT and abdominopelvic MRI, all of which show no evidence of recurrence. Gynecological history The patient had their menarche at 16 years old, and had 30-day menstrual cycles, menses lasting 5 days and a moderate flow. The patient was married at 29 years old and had their first live birth at 31 years via cesarean section. Their obstetric history was G3P1A2; they had two elective abortions at ages 30 and 38 years, both uneventful. Discussion ETT typically occurs in women of reproductive age, most commonly between the ages of 15 and 48 years, and with a median age of 33–40 years (Horowitz et al., 2017; Rodríguez-Trujillo et al., 2017; Park and Bae, 2016), with rare cases reported in postmenopausal women (Macdonald et al., 2008). The present patient, aged 47 years, is consistent with the typical age of ETT occurrence. ETT can arise after various types of gestation, most frequently following term pregnancy. The median interval from the antecedent pregnancy to diagnosis is ∼76 months (Frijstein et al., 2019), with the longest reported interval exceeding 30 years. The present patient had a history of one cesarean delivery and two induced abortions, but it was not possible to determine which gestation was associated with tumor development. In cases such as this, short tandem repeat analysis may aid in the establishment of the genetic origin of the neoplasm. The most common clinical manifestation of ETT is abnormal vaginal bleeding. In some patients, the initial presentation may be related to metastatic disease, such as hemoptysis or chest tightness due to pulmonary metastasis. Others may be asymptomatic, with the diagnosis made incidentally (Davis et al., 2015). Rationale for primary urachal origin In a small number of patients, the disease presents solely as extrauterine metastatic lesions without detection of a primary uterine lesion. Among these, isolated pulmonary lesions are the most common. Such cases may originate from primary malignant transformation of migrated trophoblasts and are referred to as extrauterine primary ETT. This patient, the tumor was incidentally discovered following surgery for a urachal cyst; however, occult primary uterine cancer with metastasis cannot be ruled out. Although no uterine evaluation was performed during the initial treatment, post-recurrence assessments, including pelvic MRI, uterine exploration and postoperative pathological examination, revealed no evidence of a primary uterine lesion. No chemotherapy was administered after the initial surgery It is also highly unlikely that a uterine lesion would have resolved spontaneously without treatment. Therefore, the possibility of occult primary uterine cancer with metastasis is relatively low, and the patient was diagnosed with primary extrauterine ETT. About the Urachal Origin was based on the preoperative ultrasound and the operative record from the external hospital, the mass was localized to the urachus. Therefore, it is considered a urachus primary ETT. Unlike other forms of GTN, β-hCG levels in ETT are typically low. In 70% of cases, β-hCG levels remain at <2500 IU/l, which is markedly lower than that observed in choriocarcinoma. Extremely low (negative) or markedly elevated (>10,000 IU/l) levels are uncommon, occurring in only 6.8 and 7.1% of cases, respectively. Moreover, serum β-hCG does not reliably correlate with tumor dissemination or metastasis (Jiang and Xiang, 2018). This complicates diagnosis in the present patient, whose pretreatment β-hCG level was only 20 IU/l, which was not further investigated before the first surgery. Clinicians should carefully evaluate abnormal laboratory findings to avoid misdiagnosis or delayed diagnosis. Preoperative diagnosis of ETT is challenging and definitive diagnosis requires histopathological examination. In general specimens, the tumor typically appears as solid or mixed solid-cystic mass, often with hemorrhage and necrosis. IHC also serves a critical role: Epithelial markers, such as CKs (AE1/AE3, CK18), epithelial membrane antigen, E-cadherin, p63, cyclin E and HLA-G, are usually positive, whereas trophoblastic markers, including hPL and hCG, show only focal positivity. In the present patient, tumor cells stained positive for CK18, inhibin-α and p63, whereas hPL and β-hCG-α were negative, consistent with the diagnostic profile of ETT. Furthermore, immunohistochemistry can be employed to further exclude primary urachal malignancy. Urachal urothelial carcinoma shares several immunohistochemical features with ETT, including CK7+, GATA3+, and p63+. However, inhibin-α positivity and PLAP positivity, as seen in our case, are characteristic of trophoblastic lineage and are not typically observed in urothelial carcinoma. Urachal adenocarcinoma is usually CK20+/CDX2+, whereas our case was CK20-. Although short tandem repeat (STR) analysis—the gold standard for confirming gestational origin—was not performed due to condition restriction, the IHC profile, together with the clinical history (prior gestations) and elevated β-hCG, strongly supports the diagnosis of ETT of urachus. Ultrasound, CT and MRI lack specificity in diagnosing ETT. Surgery is the most important treatment for ETT, in contrast to choriocarcinoma where chemotherapy predominates. For tumors confined to the uterus, total or radical hysterectomy can achieve complete remission. In patients with metastatic disease, resection of all identifiable lesions remains beneficial for improving prognosis (Liu et al., 2022). Whether ovarian preservation is necessary remains controversial. Since ETT is not hormone-dependent and ovarian metastasis is rare, routine oophorectomy may not be indicated. Decisions should be individualized, taking into account age, tumor stage, metastatic spread, family history of ovarian cancer and other relevant factors (Liu et al., 2022). Reports of fertility-sparing surgery in ETT are exceedingly rare, with only 10 stage I cases described (Davis et al., 2015; Zhang et al., 2019; Tse et al., 2018; Lok et al., 2020); of these, two resulted in successful live births, two in early miscarriages, and two developed recurrence or progression during follow-up. Thus, fertility-sparing surgery is currently not recommended. Surgery is also the most effective treatment for recurrent or chemoresistant disease, particularly for isolated or localized lesions where complete resection can reduce tumor burden and prolong survival (Zhang et al., 2014). In the present patient, the recurrence was solitary, localized to the abdominal wall and considered resectable. Although preoperative imaging did not reveal uterine involvement, given that most ETTs originate in the uterus, and considering the age of the patient (47 years) and the absence of fertility requirements, a total hysterectomy with bilateral salpingectomy was performed in addition to abdominal wall tumor resection. The role of adjuvant chemotherapy in ETT remains controversial. However, several prognostic factors, including being aged >40 years old, an interval of >4 years from antecedent pregnancy, a mitotic index of >5/10 high-power fields, high Ki-67 expression, multifocal uterine lesions and extrauterine involvement, have been associated with poorer outcomes in ITT. In such patients, adjuvant chemotherapy may be considered (Zong et al., 2019). Regimens include EMA-CO, EMA-EP, FEAV, PEB and MICE; however, given the rarity of ETT, no consensus exists regarding the optimal regimen, indications or duration. In the present study, the patient did not receive adjuvant chemotherapy after the initial surgery, which likely resulted in recurrence after 13 months. ICIs represent a promising therapeutic option for recurrent or metastatic GTN. GTNs contain paternal genetic material and most trophoblastic tumors exhibit high PD-L1 expression (Wang et al., 2025), providing a strong rationale for immunotherapy. Several clinical studies have demonstrated a notable benefit in patients with GTN (Bolze et al., 2017). Although data specific to ETT are limited, Bolze et al. (Ghorani et al., 2017) and Zong et al. (Bell et al., 2021) reported frequent PD-L1 expression in ETT, although at lower levels than in choriocarcinoma and PSTT. In a pooled review of five refractory ETT cases (Choi et al., 2019; Pisani et al., 2021; Helbig et al., 2023), four patients (one with high-risk stage I and three with stage IV cancer) achieved remission and long-term survival after ICI therapy, whereas only one patient with mixed ETT/PSTT (stage III recurrent) died of disease progression. Further studies are needed to define the optimal duration, patient selection and long-term safety of maintenance immunotherapy in ETT. Consider the risk of disease recurrence, combination chemotherapy regimens such as EMA-CO or EMA-EP should be prioritized. The integration of immunotherapy has demonstrated favorable therapeutic outcomes in recurrent GTN. Considering the limited sensitivity of ETT to chemotherapy, combined with the patient's high CPS score and PD-L1 positivity, this patient theoretically qualifies for the benefits of combined immunotherapy. Therefore, the administration of combination chemotherapy and immunotherapy aims to improve patient prognosis.The patient received four cycles of combination chemotherapy (EMA-CO) with camrelizumab, achieving complete remission. Serum β-hCG levels remained within the normal range and imaging showed no evidence of recurrence. Although immunotherapy maintenance was recommended, the patient refused; they are currently under close surveillance, with no signs of recurrence at follow-up.We acknowledge that the treatment include surgery, EMA-CO chemotherapy, and PD-1 inhibitors are conventional in the management of ETT. Although the treatment strategy itself is not novel, this study provides the first evidence of the safety and efficacy of EMA-CO+ camrelizumab in urachus primary ETT, offering a reference for future similar cases. The combination of chemotherapy and immunotherapy in a PD-L1 high (CPS 80) recurrent ETT adds to the limited body of evidence supporting ICIs in ETT. We emphasize the importance of complete surgical resection: Since the recurrence site in this case was located on the abdominal wall (at the site of previous surgical scar), it suggests that minimal residual tissue may have been present during the initial surgery. Therefore, in second surgery, we emphasize complete resection. Clinical implications This case provides several practical insights for clinicians: First, when an umbilical urachal cyst is incidentally detected in women of childbearing age, the possibility of gestational trophoblastic tumor (particularly ETT) should be considered even if serum β-hCG levels are only mildly elevated; Second, a comprehensive immunohistochemical panel incorporating trophoblastic markers (inhibin α, PLAP, GATA3, p63) and epithelial markers (CK7, CK20) is crucial for differentiating ETT from more common malignant tumors of the urachus; Third, achieving complete surgical resection with negative margins is paramount whether during initial treatment or recurrence surgery—as demonstrated in this case, incomplete initial resection may increase the risk of local recurrence, whereas complete resection after recurrence improves patient prognosis; Fourth, for recurrent PD-L1-positive ETT, the combination of chemotherapy with PD-1 blockade therapy is feasible and highly effective, supported by a CPS score as high as 80; Finally, although the treatment strategy for ETT is well-established, its successful application in this unprecedented anatomical structure (the urachus) expands the clinical evidence base and provides guidance for future diagnostic and therapeutic decisions in similar cases. Availability of data and materials The data generated in the present study may be requested from the corresponding author. Generative AI statement The authors declare that no Generative AI was used in the creation of this manuscript. Patient consent for publication Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data. CRediT authorship contribution statement Lingting Meng: Writing – review & editing, Writing – original draft, Data curation. Bin Yang: Software, Investigation. Jiaqi Ma: Investigation, Data curation. Juan Zhang: Investigation, Data curation. Lei Lei: Project administration. Ye Hong: Funding acquisition. Xiaojun Hu: Writing – review & editing, Project administration. Ethics approval and consent to participate Not applicable. Funding The present study was funded by the Shaanxi Provincial Key R&D Program (grant no. 2024SF-YBXM-133). Declaration of competing interest The authors declare that they have no competing interests. Acknowledgements Not applicable. References Associated Data Data Availability Statement The data generated in the present study may be requested from the corresponding author.